Pegfilgrastim (Neulasta, Fulphila, Ziextenzo, Udenyca, Nyvepria)
Other Medications · Approved since 2002
Description
Pegfilgrastim is a long-acting pegylated granulocyte colony-stimulating factor (G-CSF) used as supportive care in colorectal cancer treatment. It prevents chemotherapy-induced neutropenia by stimulating the bone marrow to produce white blood cells, particularly neutrophils. In CRC patients receiving myelosuppressive chemotherapy regimens, pegfilgrastim reduces the risk of febrile neutropenia and allows for maintenance of chemotherapy dose intensity.
Mechanism of Action
Pegfilgrastim binds to and activates G-CSF receptors on neutrophil precursor cells in the bone marrow, stimulating their proliferation, differentiation, and maturation into functional neutrophils. The pegylation increases the drug's half-life by reducing renal clearance, while neutrophil-mediated clearance provides self-regulating pharmacokinetics that decrease as neutrophil counts recover.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Neulasta, Fulphila, Ziextenzo, Udenyca, Nyvepria |
| Category | Other Medications |
 Status | FDA Approved |
 EMA Status | EMA Approved |
 Spain Access | Hospital use other indication |
| Administration | Subcutaneous |
| Year Approved | 2002 |
| Clinical Trials | 4 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.